2,387 results match your criteria Antitrust Law Journal[Journal]


Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.

Authors:
Diletta Danieli

Health Econ Policy Law 2020 May 21:1-12. Epub 2020 May 21.

Law Department, Postdoctoral Research Fellow in EU Law, University of Verona, Verona, Italy.

The paper addresses the issue of excessive price abuse under Article 102(a) of the Treaty on the Functioning of the European Union (TFEU), by drawing inspiration from a recent stream of cases (developed first at the national and then at the EU level) involving pharmaceutical companies marketing off-patent drugs. In particular, the two 'most advanced' cases are analysed: Aspen in Italy and Pfizer/Flynn in the United Kingdom. This new-found attention towards exploitative practices in the form of excessive and unfair pricing by dominant undertakings that have traditionally been subject to a cautious antitrust scrutiny seems worth exploring for a number of reasons, as illustrated in the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1744133120000109DOI Listing

Price Transparency: Empowering Patient Choice and Promoting Provider Competition.

J Med Syst 2020 Mar 5;44(4):80. Epub 2020 Mar 5.

Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, USA.

In light of recent health policy efforts to promote price transparency, this perspective reviews the challenges and benefits of price transparency. These price transparency efforts include the recent executive order and associated rulemaking directing providers to disclose negotiated and out-of-pocket costs for "shoppable" healthcare services. First, we explore the previous efforts of states and health plans targeted at price transparency, reviewing lessons for future implementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10916-020-01553-2DOI Listing

Rising Prices and Health Care "Empires".

Authors:
Andrew B Bindman

JAMA 2020 Mar;323(9):815-816

Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2020.1370DOI Listing

Antitrust analysis with upward pricing pressure and cost efficiencies.

PLoS One 2020 8;15(1):e0227418. Epub 2020 Jan 8.

Economics Department, The University of Kansas, Lawrence, KS, United States of America.

We investigate the accuracy of UPP as a tool in antitrust analysis when there are cost efficiencies from a horizontal merger. We include merger-specific cost efficiencies in a tractable manner in the model and extend the standard UPP formulation to account for these efficiencies. The efficacy of the new UPP formulations is analyzed using Monte Carlo simulation of 40,000 mergers (8 scenarios, 5,000 mergers in each scenario). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0227418PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949007PMC

Fighting Injustice: A Historical Review of the National Chiropractic Antitrust Committee.

J Chiropr Humanit 2019 Dec 10;26:19-30. Epub 2019 Dec 10.

National University of Health Sciences, Lombard, Illinois.

Objective: The purpose of this article is to provide a historical summary of the National Chiropractic Antitrust Committee (NCAC), a nonprofit organization that provided needed support for the Wilk et al v American Medical Association et al lawsuit, considered to be one of the most important legal cases in the history of the chiropractic profession.

Methods: We reviewed journal articles, court documents, texts, interviews, and primary historical documents and created a chronology of events that was then synthesized into a factual account of the NCAC.

Results: The primary function of the NCAC was to raise money to support legal steps necessary against actions of the nature of boycott, restraint of trade, or any acts deemed unlawful against the chiropractic profession. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.echu.2019.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911905PMC
December 2019

Panel data to investigate pricing behavior in the Spanish retail fuel market.

Data Brief 2020 Feb 27;28:104880. Epub 2019 Nov 27.

UNED, Spain.

The data described in this article were collected daily over the period 18 August 2014 to 15 June 2015 from the website of the Spanish Ministry of Industry, Energy and Tourism http://geoportalgasolineras.es. The database includes information on almost all gas stations located in Spain that sell to the public. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dib.2019.104880DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911964PMC
February 2020

Do All Hospital Systems Have Market Power? Association Between Hospital System Types and Cardiac Surgery Prices.

Authors:
Sung W Choi Avi Dor

Health Serv Res Manag Epidemiol 2019 Jan-Dec;6:2333392819886414. Epub 2019 Nov 11.

Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.

Objective: This study explores the price implications of hospital systems by analyzing the association of system characteristics with selected cardiac surgery pricing.

Data Source: Using a large private insurance claim database, the authors identified 11 282 coronary artery bypass graft (CABG) cases and 49 866 percutaneous coronary intervention (PCI) cases from 2002 to 2007.

Study Design: We conducted a retrospective observational study using generalized linear models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2333392819886414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851608PMC
November 2019

Mind the Gap: Antitrust, Health Disparities and Telemedicine.

Am J Law Med 2019 May;45(2-3):171-187

2018-2019 Michigan Grotius Research Scholar, Research Fellow at Edmond J. Safra Center for Ethics, Tel Aviv University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0098858819860607DOI Listing

Higher Drug Prices from Anticompetitive Conduct: Three Case Studies.

J Leg Med 2019 Apr-Jun;39(2):151-167

U.S. consumers pay high drug prices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01947648.2019.1645540DOI Listing
January 2020

Parallel imports, price controls, and innovation.

J Health Econ 2019 07 12;66:163-179. Epub 2019 Jun 12.

European Commission, Chief Economist Team, DG Competition, 1049 Brussels, Belgium. Electronic address:

The impact of parallel trade on innovation in R&D-intensive industries, such as pharmaceuticals, is a hotly debated question in antitrust and IP policy. The well-known argument that parallel trade dampens innovation by undermining firms' ability to price discriminate has been challenged by recent literature. The argument is that with endogenous price controls, parallel trade increases innovation by reducing governments' incentives to set particularly low price caps. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01676296183077
Publisher Site
http://dx.doi.org/10.1016/j.jhealeco.2019.05.002DOI Listing
July 2019
7 Reads

The Association Between Hospital Concentration And Insurance Premiums In ACA Marketplaces.

Health Aff (Millwood) 2019 04;38(4):668-674

Ashish K. Jha ( ) is dean of global strategy, K.T. Li Professor of Global Health, and director of the Harvard Global Health Institute at the Harvard T. H. Chan School of Public Health.

Keeping the Affordable Care Act's health insurance Marketplaces financially accessible is critically important to their viability. While the relationship between the number of insurers and Marketplace premiums has received widespread attention, the role of hospital market concentration on premiums has been understudied. We examined the relationship between hospital market concentration and Marketplace insurance premiums in the period 2014-17, the extent to which the number of insurers modified this relationship, and whether community-level characteristics were associated with varying levels of concentration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2018.05491DOI Listing
April 2019
16 Reads

Next Phase in Effective Cost Control in Health Care.

JAMA 2019 Mar;321(12):1151-1152

Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2019.1608DOI Listing
March 2019
9 Reads

Hospital Prices Grew Substantially Faster Than Physician Prices For Hospital-Based Care In 2007-14.

Health Aff (Millwood) 2019 02;38(2):184-189

John Van Reenen is the Gordon Y. Billard Professor in Management and Economics, Sloan School of Management, Massachusetts Institute of Technology, in Cambridge.

Evidence suggests that growth in providers' prices drives growth in health care spending on the privately insured. However, existing work has not systematically differentiated between the growth rate of hospital prices and that of physician prices. We analyzed growth in both types of prices for inpatient and hospital-based outpatient services using actual negotiated prices paid by insurers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2018.05424DOI Listing
February 2019
1 Read

Pharmaceuticals and Medical Devices: Business Practices.

Issue Brief Health Policy Track Serv 2018 Dec 24;2018:1-38. Epub 2018 Dec 24.

Thomson Reuters Accelus.

View Article

Download full-text PDF

Source
December 2018
3 Reads

Business of Health. Business of Health Insurance.

Issue Brief Health Policy Track Serv 2018 Dec 24;2018:1-42. Epub 2018 Dec 24.

Thomson Reuters Accelus.

View Article

Download full-text PDF

Source
December 2018
9 Reads

Recent Developments at DG Competition: 2017/2018.

Rev Ind Organ 2018 1;53(4):653-679. Epub 2018 Nov 1.

9Directorate-General for Competition, European Commission, MADO 17/014, 1049 Brussels, Belgium.

The Directorate General for Competition at the European Commission enforces competition law in the areas of antitrust, merger control, and state aids. This year's article provides first a general presentation of the role of the Chief Competition Economist's team and surveys some of the main achievements of the Directorate General for Competition over 2017/2018. The article then reviews: the Google Search (Shopping) case, the role of price discrimination in state aid cases; and the use of counterfactuals in merger cases where alternative transactions might have occurred absent the merger. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11151-018-9671-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267239PMC
November 2018
1 Read

Geographic Market Definition in the Merger Guidelines: A Retrospective Analysis.

Rev Ind Organ 2018 15;53(3):453-475. Epub 2018 Sep 15.

Cornerstone Research, San Francisco, USA.

Since the initial Merger Guidelines in 1968, the Department of Justice and Federal Trade Commission have revised their merger enforcement screen over the course of six versions. This article examines the evolution of the geographic market component of the Guidelines and the economic implications of changing standards of market delineation on merger enforcement. Using an illustration from the beer industry, we chronicle the development of geographic market definition and its varying effects on merger enforcement over the past 50 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11151-018-9658-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208606PMC
September 2018
1 Read

The California Competitive Model: How Has It Fared, And What's Next?

Health Aff (Millwood) 2018 09;37(9):1417-1424

Jack Zwanziger is a professor of health policy and administration at the University of Illinois at Chicago.

California became very successful in controlling rising health care costs by promoting price competition through market-based, managed care policies. However, recent data reveal that the state has not been able sustain its initial success in controlling growth in hospital prices. Two powerful trends emerged in California that eroded the conditions needed to sustain price competition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2018.0418DOI Listing
September 2018
16 Reads

The Protection of Patients Under the Clayton Act.

Fordham Law Rev 2018 Apr;86(5):2473-509

The vast consolidation among health-care providers in the aftermath of the Affordable Care Act's enactment has led to much debate over the benefits of mergers in the health-care industry. In 2016, the Federal Trade Commission filed motions in federal court to enjoin three hospital mergers in various parts of the country. This amounted to more challenges to hospital mergers in a single year than any year in recent history. Read More

View Article

Download full-text PDF

Source
April 2018
1 Read

Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.

JAMA 2018 06;319(22):2271-2272

Rutgers Law School, Rutgers University, Camden, New Jersey.

View Article

Download full-text PDF

Source
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.20
Publisher Site
http://dx.doi.org/10.1001/jama.2018.3478DOI Listing
June 2018
6 Reads

Effect of Practice Ownership on Work Environment, Learning Culture, Psychological Safety, and Burnout.

Ann Fam Med 2018 04;16(Suppl 1):S44-S51

Department of Family Medicine and Population Health, Virginia Commonwealth University, Richmond, Virginia.

Purpose: Physicians have joined larger groups and hospital systems in the face of multiple environmental challenges. We examine whether there are differences across practice ownership in self-reported work environment, a practice culture of learning, psychological safety, and burnout.

Methods: Using cross-sectional data from staff surveys of small and medium-size practices that participated in EvidenceNOW in Virginia, we tested for differences in work environment, culture of learning, psychological safety, and burnout by practice type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1370/afm.2198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891313PMC
April 2018
39 Reads

Lost World: Discovering Medical Antitrust Law's Uses and Abuses.

Authors:
Donald McClarey

J Leg Med 2017 Jul-Dec;37(3-4):541-558

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01947648.2017.1385042DOI Listing
July 2019
3 Reads

Health Care Efficiencies: Consolidation and Alternative Models vs. Health Care and Antitrust Regulation - Irreconcilable Differences?

Authors:
Michael W King

Am J Law Med 2017 Nov;43(4):426-467

Michael King, Shareholder, Brownstein Hyatt Farber Schreck, specializing in complex health care transactional and finance matters, including structuring joint ventures and management arrangements, mergers and acquisitions, and financing transactions. The author would like to thank Brownstein Shareholder Rich Benenson for his contributions on antitrust litigation, and Associate Kathleen Snow for her contributions on health care regulatory matters. The viewpoints and opinions expressed in this article do not necessarily reflect those of Brownstein or its clients.

Despite the U.S. substantially outspending peer high income nations with almost 18% of GDP dedicated to health care, on any number of statistical measurements from life expectancy to birth rates to chronic disease, the U. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0098858817753407DOI Listing
November 2017
7 Reads

Non-profit Drug Research and Development at a Crossroads.

Pharm Res 2018 Feb 7;35(3):52. Epub 2018 Feb 7.

Claude Bernard University, Laboratoire Parcours Santé Systémique EA 4129, Lyon, France.

In wealthy nations, non-profit drug R&D has been proposed to reduce the prices of medicines. We sought to review the ethical and economic issues concerning non-profit drug R&D companies, and the possible impact that their pricing strategy may have on the innovation efforts from for-profit companies targeting the same segment of the pharmaceutical market. There are two possible approaches to pricing drugs developed by non-profit R&D programs: pricing that maximises profits and "affordable" pricing that reflects the cost of manufacturing and distribution, plus a margin that ensures sustainability of the drug supply. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-018-2351-3DOI Listing
February 2018
24 Reads

Pharmaceuticals and Medical Devices: Business Practices.

Issue Brief Health Policy Track Serv 2017 Dec 26;2017:1-38. Epub 2017 Dec 26.

View Article

Download full-text PDF

Source
December 2017
4 Reads

Hospital Consolidation: FTC May be a Stick in the Spokes of Hospital Mergers.

Manag Care 2017 12;26(12):29-30

For instance, in the case of Sanford Health's acquisition of Mid Dakota Clinic in North Dakota, the agency challenged the deal, claiming that the merged entity would control 75% or more of primary care and other health services in the Bismarck-Mandan metropolitan area. Read More

View Article

Download full-text PDF

Source
December 2017

Sharing, samples, and generics: an antitrust framework.

Cornell Law Rev 2017;103(1):1-64

Rutgers Law School.

Rising drug prices are in the news. By increasing price, drug companies have placed vital, even life-saving, medicines out of the reach of consumers. In a recent development, brand firms have prevented generics even from entering the market. Read More

View Article

Download full-text PDF

Source
January 2018
3 Reads

Recent Developments at DG Competition: 2016/2017.

Rev Ind Organ 2017 9;51(4):397-422. Epub 2017 Nov 9.

Directorate-General for Competition, European Commission, MADO 17/026, 1049 Brussels, Belgium.

The Directorate General for Competition at the European Commission enforces competition law in the areas of antitrust, merger control, and state aids. This year's article provides first a general presentation of the role of the Chief Competition Economist's team and surveys the main achievements of the Directorate General for Competition over 2016/2017. The article then reviews the economic work undertaken in one merger case between Dow/DuPont, which raised specific issues related to innovation, as well as in an antitrust case on parity clauses related to Amazon e-books. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11151-017-9592-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684248PMC
November 2017
8 Reads

Vertical Integration of Hospitals and Physicians: Economic Theory and Empirical Evidence on Spending and Quality.

Med Care Res Rev 2018 08 29;75(4):399-433. Epub 2017 Aug 29.

1 University of Michigan, Ann Arbor, MI, USA.

Hospital-physician vertical integration is on the rise. While increased efficiencies may be possible, emerging research raises concerns about anticompetitive behavior, spending increases, and uncertain effects on quality. In this review, we bring together several of the key theories of vertical integration that exist in the neoclassical and institutional economics literatures and apply these theories to the hospital-physician relationship. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1077558717727834DOI Listing
August 2018
7 Reads

Beyond Antitrust: Health Care And Health Insurance Market Trends And The Future Of Competition.

Health Aff (Millwood) 2017 09;36(9):1572-1577

Stuart H. Altman is a professor of national health policy at the Heller School for Social Policy and Management, Brandeis University, in Waltham, Massachusetts.

The United States relies on competition to balance costs and quality in the health care system. But concentration is increasing throughout the hospital, physician, and insurer markets. Midsize community hospitals face declining demand and growing competition from both larger hospitals and smaller freestanding diagnostic and surgical centers, leaving the midsize hospitals vulnerable to closure or merger with other facilities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2017.0555DOI Listing
September 2017
5 Reads

Coping With Concentration.

Authors:
Thomas L Greaney

Health Aff (Millwood) 2017 09;36(9):1564-1571

Thomas L. Greaney is a professor at the University of California Hastings College of Law, in San Francisco. At the time of this work, he was the Chester A. Myers Professor of Law at Saint Louis University School of Law, in Missouri.

Provider market power is a powerful driver of high health care costs in the United States. Despite decades of antitrust litigation and regulatory interventions, the problem has worsened and threatens to undermine the benefits of market-based policies. A critical but neglected challenge for all health care reform proposals relying on market competition to address costs is finding effective tools to address the extant market power of dominant hospitals, hospital systems, and many specialty physician practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2017.0558DOI Listing
September 2017
5 Reads

Physician Practice Consolidation Driven By Small Acquisitions, So Antitrust Agencies Have Few Tools To Intervene.

Health Aff (Millwood) 2017 09;36(9):1556-1563

Christopher Ody is a research assistant professor in the Kellogg School of Management, Northwestern University.

The growing concentration of physician markets throughout the United States has been raising antitrust concerns, yet the Department of Justice and the Federal Trade Commission have challenged only a small number of mergers and acquisitions in this field. Using proprietary claims data from states collectively containing more than 12 percent of the US population, we found that 22 percent of physician markets were highly concentrated in 2013, according to federal merger guidelines. Most of the increases in physician practice size and market concentration resulted from numerous small transactions, rather than a few large transactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2017.0054DOI Listing
September 2017
2 Reads

Corporate Investors Increased Common Ownership In Hospitals And The Postacute Care And Hospice Sectors.

Health Aff (Millwood) 2017 09;36(9):1547-1555

David G. Stevenson is an associate professor in the Department of Health Policy, Vanderbilt University School of Medicine.

The sharing of investors across firms is a new antitrust focus because of its potential negative effects on competition. Historically, the ability to track common investors across the continuum of health care providers has been limited. Thus, little is known about common investor ownership structures that might exist across health care delivery systems and how these linkages have evolved over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2017.0591DOI Listing
September 2017
59 Reads

Health Care Market Concentration Trends In The United States: Evidence And Policy Responses.

Authors:
Brent D Fulton

Health Aff (Millwood) 2017 09;36(9):1530-1538

Brent D. Fulton is an assistant adjunct professor in the School of Public Health at the University of California, Berkeley.

Policy makers and analysts have been voicing concerns about the increasing concentration of health care providers and health insurers in markets nationwide, including the potential adverse effect on the cost and quality of health care. The Council of Economic Advisers recently expressed its concern about the lack of estimates of market concentration in many sectors of the US economy. To address this gap in health care, this study analyzed market concentration trends in the United States from 2010 to 2016 for hospitals, physician organizations, and health insurers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2017.0556DOI Listing
September 2017
2 Reads

Hospital and Health Insurance Markets Concentration and Inpatient Hospital Transaction Prices in the U.S. Health Care Market.

Authors:
Seidu Dauda

Health Serv Res 2018 04 11;53(2):1203-1226. Epub 2017 May 11.

World Bank Group, MC3-401, 1818 H Street NW, Washington, DC.

Objective: To examine the effects of hospital and insurer markets concentration on transaction prices for inpatient hospital services.

Data Sources: Measures of hospital and insurer markets concentration derived from American Hospital Association and HealthLeaders-InterStudy data are linked to 2005-2008 inpatient administrative data from Truven Health MarketScan Databases.

Study Design: Uses a reduced-form price equation, controlling for cost and demand shifters and accounting for possible endogeneity of market concentration using instrumental variables (IV) technique. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1475-6773.12706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867178PMC
April 2018
53 Reads

Cross-Market Mergers in Healthcare: Adapting Antitrust Regulation to Address a Growing Concern.

Cornell Law Rev 2017 Apr;102(3):821-52

View Article

Download full-text PDF

Source
April 2017
1 Read

Patient Inducements - High Graft or High Value?

N Engl J Med 2017 Mar;376(12):1107-1109

From the Robert Wood Johnson Foundation Clinical Scholars Program, University of Pennsylvania (K.H.C., D.A.A., D.T.G.), and the Cpl. Michael J. Crescent Veterans Affairs Medical Center (K.H.C., D.A.A.) - both in Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp1613274DOI Listing
March 2017
1 Read

Pharmaceuticals and Medical Devices: Business Practices.

Issue Brief Health Policy Track Serv 2016 Dec 27;2016:1-38. Epub 2016 Dec 27.

View Article

Download full-text PDF

Source
December 2016
10 Reads

Business of Health: Business of Health Insurance.

Issue Brief Health Policy Track Serv 2016 Dec 27;2016:1-76. Epub 2016 Dec 27.

View Article

Download full-text PDF

Source
December 2016
30 Reads

Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.

Authors:
Mark S Levy

Am Univ Law Rev 2016;66(1):247-303

Now, more than ever before, pharmacologists are contributing medical advances to confront ravaging disease. They are developing drugs to mitigate the effects of Alzheimer’s, HIV, multiple sclerosis, and various forms of cancer. To capitalize on the opportunity, brand-name pharmaceutical firms are patenting these drugs, consequently guarding formulas and, with it, profits. Read More

View Article

Download full-text PDF

Source
March 2017
14 Reads

Anthem sees Trump's DOJ as its wingman.

Mod Healthc 2017 Feb;47(9):13

It reads like an ugly divorce. Court records show two former partners accusing each other of lies and sabotage. Read More

View Article

Download full-text PDF

Source
February 2017
1 Read

The engagements and eventual breakups of the insurance giants.

Mod Healthc 2017 Feb;47(8):12-13

View Article

Download full-text PDF

Source
February 2017
1 Read

Emboldened, the FTC Seems Ready to Fight More Mergers.

Manag Care 2016 11;25(11):13-14

A court ruling to block a merger in central Pennsylvania could mean more FTC sticks in the spokes of health care system mergers. Read More

View Article

Download full-text PDF

Source
November 2016
1 Read

A License to Labor.

Authors:
Suzanne Weiss

State Legis 2017 01;43(1):20-3

View Article

Download full-text PDF

Source
January 2017
3 Reads

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis.

Z Rheumatol 2017 03;76(2):185

Department of Medicine, Justus Liebig University Giessen, Giessen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-016-0256-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344950PMC
March 2017
1 Read

Aetna's antitrust defeat may signal the end of health insurance mega-mergers.

Mod Healthc 2017 Jan;47(5):8-9

The Aetna-Humana antitrust ruling will complicate any deal involving health insurers with significant Medicare Advantage holdings. That combined with the uncertain future of the ACA mean the industry is likely to see a wave of smaller tie-ups. Read More

View Article

Download full-text PDF

Source
January 2017
2 Reads

States sue generic drug makers for alleged price fixing.

Authors:
Michael McCarthy

BMJ 2016 Dec 19;355:i6764. Epub 2016 Dec 19.

Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.i6764DOI Listing
December 2016
5 Reads

Quantifying Geographic Variation in Health Care Outcomes in the United States before and after Risk-Adjustment.

PLoS One 2016 14;11(12):e0166762. Epub 2016 Dec 14.

The Alerion Institute and Alerion Advisors, LLC, North Garden, Virginia, United States of America.

Background: Despite numerous studies of geographic variation in healthcare cost and utilization at the local, regional, and state levels across the U.S., a comprehensive characterization of geographic variation in outcomes has not been published. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0166762PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156342PMC
July 2017
83 Reads